Skip to main content
. 2019 Jan 25;14(1):e0210198. doi: 10.1371/journal.pone.0210198

Fig 6. Immunohistochemistry and western blotting of ipsilateral hemisphere tissue at day 21.

Fig 6

(A) Injection of either MNCs or RACs significantly increased VEGF-positive cells in the peri-infarct area at day 21 (PBS: n = 8, MNCs: n = 7, RACs: n = 9) (*P<0.05, respectively, Kruskal-Wallis test). (B) Injection of RACs (1 x 104/50 μL) significantly increased VEGF in the peri-infarct area, as determined by western blotting, at day 21 (*P<0.05, Kruskal-Wallis test) (PBS: n = 6, MNCs: n = 6, RACs: n = 7). (C) Injection of RACs (1 x 104 /50 μL) did not increase IL-10-positive cells in the peri-infarct area at day 21 (PBS: n = 8, MNCs: n = 7, RACs: n = 9). (D) Injection of RACs (1 x 104 /50 μL) did not increase IL-10 in the peri-infarct area, as determined by western blotting, at day 21 (PBS: n = 6, MNCs: n = 6, RACs: n = 7).